AN IN VIVO MODEL FOR TESTING INHIBITION OF ARGININE-INDUCED INSULIN AND GLUCAGON RELEASE BY SOMATOSTATIN ANALOGS
Authors:
- Ariel GordinAGAriel Gordin
- Chester MeyersCMChester Meyers
- Akira ArimuraAAAkira Arimura
- David H. CoyDCDavid H. Coy
- Andrew V. SchallyASAndrew V. Schally
- 1 December 1977
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 86 (4) , 833-841
Abstract
The secretion of these pancreatic hormones was stimulated in rat by infusion of arginine. The plasma insulin level increased almost to a maximum after an infusion of 10 min, while plasma glucagon rose more slowly, reaching its maximum only after a 30 min infusion. Concomitant infusion of graded doses of somatostatin (2.5, 10, 40 and 160 .mu.g/100 g body wt) for 30 min inhibited both insulin and glucagon release in a dose-dependent manner, enabling the testing of somatostatin analogs for insulin and glucagon-suppressive activity in a semi-quantitative manner. Using this animal model, 3 analogs of somatostatin, [D-cys14]-, [Ala2, D-Cys14]- and [D-Trp8, D-Cys14]somatostatin were tested in a 4 point assay. They all showed dissociated activity in inhibiting the secretion of glucagon more than that of insulin.Keywords
This publication has 3 references indexed in Scilit:
- Somatostatin analogs which inhibit glucagon and growth hormone more than insulin releaseBiochemical and Biophysical Research Communications, 1977
- Dissociation of somatostatin effects. Peptides inhibiting the release of growth hormone but not glucagon or insulin in ratsLife Sciences, 1976
- Solid phase synthesis of growth hormone-release inhibiting factorBiochemical and Biophysical Research Communications, 1973